** Brokerage Jefferies raises its PT for Eli Lilly (LLY.N) to $625 from $615 ** The new price target represents a 17.7% upside to the stock’s last close ** LLY’s diabetes medication Mounjaro can achieve about 50% peak market share of all the GLP-1’s in OSA (obstructive sleep apnea)- Jefferies ** GLP-1 drugs, originally developed to help control blood sugar in patients with type 2 diabetes, also suppress appetite and promote a feeling of fullness ** OSA is a disorder strongly associated with obesity where one’s airway passage gets disrupted during sleep ** Including session moves, LLY’s shares up ~47.5% YTD